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ABSTRACT
Human respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract disease in infants and young children and
an important respiratory pathogen in the elderly and immunocompromised. While population-wide molecular epidemiology
studies have shownmultiple cocirculating RSV genotypes and revealed antigenic and genetic change over successive seasons,
little is known about the extent of viral diversity over the course of an individual infection, the origins of novel variants, or the
effect of immune pressure on viral diversity and potential immune-escape mutations. To investigate viral population diversity in
the presence and absence of selective immune pressures, we studied whole-genome deep sequencing of RSV in upper airway
samples from an infant with severe combined immune deficiency syndrome and persistent RSV infection. The infection contin-
ued over several months before and after bone marrow transplant (BMT) from his RSV-immune father. RSV diversity was char-
acterized in 26 samples obtained over 78 days. Diversity increased after engraftment, as defined by T-cell presence, and popula-
tions reflected variation mostly within the G protein, the major surface antigen. Minority populations with known palivizumab
resistance mutations emerged after its administration. The viral population appeared to diversify in response to selective pres-
sures, showing a statistically significant growth in diversity in the presence of pressure from immunity. Defining escape muta-
tions and their dynamics will be useful in the design and application of novel therapeutics and vaccines. These data can contrib-
ute to future studies of the relationship between within-host and population-wide RSV phylodynamics.
IMPORTANCE
Human RSV is an important cause of respiratory disease in infants, the elderly, and the immunocompromised. RSV circulating
in a community appears to change season by season, but the amount of diversity generated during an individual infection and
the impact of immunity on this viral diversity has been unclear. To address this question, we described within-host RSV diver-
sity by whole-genome deep sequencing in a unique clinical case of an RSV-infected infant with severe combined immunodefi-
ciency and effectively no adaptive immunity who then gained adaptive immunity after undergoing bone marrow transplanta-
tion. We found that viral diversity increased in the presence of adaptive immunity and was primarily within the G protein, the
major surface antigen. These data will be useful in designing RSV treatments and vaccines and to help understand the relation-
ship between the dynamics of viral diversification within individual hosts and the viral populations circulating in a community.
Human respiratory syncytial virus (RSV) is the leading cause ofsevere viral respiratory disease in infants and young children
(1) and is a significant cause of morbidity and mortality in the
elderly (2) and immunocompromised (3, 4). Reinfection can take
place throughout life, although in older children and healthy
adults infection is usually associated with milder disease (5, 6).
Population-wide molecular epidemiology studies have shown
that there are multiple cocirculating RSV genotypes (where geno-
types have been defined by the sequence of the variable region of
the attachment [G] protein) that undergo a gradual replacement
in dominant genotypes over successive seasons (7–9). Studies of
RSV evolution in response to selective pressures have demon-
strated escape mutations in vitro in the G protein (10, 11), and
analyses of clinical collections of RSV sequences have found pop-
ulation-genetic evidence suggesting positive selection within the
G protein (12–14). These studies support the hypothesis that the
variation in circulating RSV genotypes reflects response to im-
mune pressure. However, little is known about the extent of viral
diversity over the course of an individual infection or the effect of
immune status on viral diversity. Additionally, studies to date
have focused almost exclusively on variations within small seg-
ments of the G protein, as these appear to be the most variable
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regions of the genome. As the G protein is a surface protein pri-
marily responsible for virus attachment to host cells and an im-
munomodulatory secreted form also exists (15), understanding
the natural diversity of the G protein in the absence of specific
immune pressure within a host is important. Likewise, under-
standing the diversity of the rest of the genome and the relation-
ship of this variation to immune pressuremay aid in development
of therapeutics and guide vaccine targets and strategies.
Recent technological advances in deep sequencing have estab-
lished a platform with which we are able to generate full-genome
assemblies without the aid of a reference and to investigate the
diversity of viral subpopulations over the course of individual in-
fections. Deep sequencing studies of chronic RNA viral infections,
such as HIV infections, have expanded our understanding of viral
evolutionary dynamics in response to immunity and drug resis-
tance (16, 17). Applying these same technologies to acute, self-
limited infections with RNA viruses such as RSV can aid in under-
standing viral pathogenesis and the role of immune pressure in
generation of viral sequence diversity. The assessment of the rela-
tionship between immune pressure and viral diversity and adap-
tation will allow for deeper understanding of the origins and dy-
namics of viral population diversity (18).
To study the within-host diversity of RSV and the role of im-
mune pressure, we investigated the viral populations from an
RSV-infected infant with severe combined immune deficiency
(SCID) who subsequently underwent a bone marrow transplant
(19). The infant developed progressive respiratory symptoms over
the month prior to hospitalization. Subsequently, nasal aspirate
samples were collected prospectively and viral loads quantified
under a research protocol designed to study RSV pathogenesis.
Treatment with 4 infusions of palivizumab had no clinical impact,
and the nasal RSV load remained unchanged. He underwent bone
marrow transplantation without prior myeloablative condition-
ing. Notably, the patient’s father was the donor, and he had lived
with the patient and had symptoms consistent with RSV infection
2 months prior to the transplant. At approximately 10 days
posttransplant (termed D 10), viral load declined and be-
came undetectable. However, the patient developed respiratory
distress. Infusion of RSV immunoglobulin (Ig), palivizumab, and
immunomodulatory therapy for possible graft-versus-host dis-
ease was associated with clinical improvement, as well as resur-
gence in nasal RSV load. The rise in absolute lymphocyte count
and CD8 cell count started around day 12 posttransplant (D12)
and likely represented proliferation of donor-derived effector
cells.
RSV samples were obtained and viral loads determined atmul-
tiple time points before and after the transplant and rise in lym-
phocyte count, thereby allowing study of longitudinally collected
samples from an individual infection and under distinct levels of
immunological and treatment-related selective pressure. Here, we
use whole-genome deep sequencing to characterize the extent and
nature of this diversity. We address the following questions. (i) Is
there viral diversity in the absence of adaptive immune pressure?
(ii) Is there viral diversity in the presence of adaptive immune
pressure? (iii) Does the amount of diversity differ between these
two states? (iv) What does the nature and context of the diversity
imply about the within-host RSV dynamics and response to im-
mune pressure?
MATERIALS AND METHODS
RSV sample preparation. Twenty-six serial nasal aspirates were obtained
quantitatively and prospectively from the patient as previously described
and maintained at 80°C (19). The study was conducted with the ap-
proval of the University of Tennessee Institutional Review Board and
included appropriate informed consent, complying with all relevant fed-
eral guidelines and institutional policies. Viral RNA was extracted from
the thawed samples using a QIAsymphony DSP virus/pathogen kit (Qia-
gen) per the manufacturer’s protocol, including the provided synthetic
poly(A). Viral RNA was eluted with 60 l of AVE buffer and stored at
80°C. All samples were treated with Turbo DNase (Life Technologies)
using the manufacturer’s rigorous treatment to ensure removal of DNA.
Deep sequencing and variant calling.RNA amplificationwas done as
previously described (20). Illumina library construction was performed
using NexteraXT (Illumina) by following the manufacturer’s protocol.
Sequencing was performed on the Illumina HiSeq2500 platform, gener-
ating paired-end 101-bp reads. To determine the host and virus compo-
sition of each library, reads were aligned to viral and host reference ge-
nomes as previously described (20). The reference genomes used were the
concatenation of the human genome assembly (GRCh37/hg19), human
rRNA sequences (NR_003286.1, NR_003287.1, V00589.1, NR_003285.2,
gi251831106:648–1601, and gi251831106:1671–3229), and the RSV-A
sequence (M74568.1). The reads were assembled using the VICUNA as-
sembly program (21). Variant calling was performed using V-Phaser 2
(22) to compare reads from each time point to the consensus sequence
from the first time point. The diversity of sites was visualized using Web-
Logo 3.3 (23).
Calculation of information content. For each time point, the popu-
lation diversity at each amino acid position was identified using V-Phaser
2 (22). For variant positions in which the dominant amino acid was no
more than 95% of the overall population, the Shannon diversity index
(Hi) was determined with the following equation: Hi   pa,ilog2pa,i,
where pa,i is the relative frequency of an amino acid at position i. The
average diversity index for theRSVpopulation at each time pointwas then
determined by summingHi over all variant positions as defined above and
dividing by the length of the consensus genome sequence from the first
time point, which was used as the reference for read-based mapping.
Analysis of average diversity.The average diversity indices were plot-
ted by time. To determine whether diversity differed before and after the
rise in lymphocyte count at day 12, the data were fitted to the linear
regression model Y 0 1A 2(A	 I), where A is the explanatory
variable, the  terms are the regression coefficients, and I is an indicator
for the final six time points (after the rise in lymphocyte count).
Comparison of within-host and population-wide diversity. To de-
termine population-wide diversity, RSV-A full-genome nucleotide se-
quenceswere downloaded fromGenBank (see Table S1 in the supplemen-
tal material). Each gene sequence was extracted, visualized, and translated
to protein sequence in SeaView (24). The Shannon diversity index was
determined as described above, ignoring sites containing degenerate nu-
cleotide calls. For the purposes of comparison of the population-wide
diversity towithin-host diversity, themaximumdiversity at each site from
all of the within-host samples was used.
Nucleotide sequence accession numbers. Sequences determined in
the course of this work have been placed in GenBank under accession
numbers KF973319 to KF973340.
RESULTS AND DISCUSSION
Deep sequencing of RSV samples. Of the 26 samples, 21 yielded
high depth of coverage across the entire coding region of the ge-
nome, one yielded lower depth of coverage, and four had far fewer
reads aligning across the genome (Table 1). Subsequent de novo
assembly of the viral reads resulted in assemblies that covered
100%, 
90%, and 60% of the coding region, respectively (see
Fig. S1 in the supplemental material). The 22 assemblies that cov-
ered 90% of the genome were largely contiguous, with few in-
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tervening gaps, while the remaining 4 assemblies contained mul-
tiple large gaps. Failure to generate contiguous assemblies
covering the entire genome in these four samples was largely due
to low viral loads as detected by quantitative culture (Table 1) and
high levels of human nucleic acid contamination (see Table S2).
These four assemblies were not used in subsequent analyses.
Reads were mapped to the de novo assembled consensus se-
quence from the first time point and amino acid variants were
determined using Vicuna and V-Phaser2 software, respectively
(21, 22). To assess population diversity at each time point, the
genome-wide average Shannon diversity index was calculated.
Fitting the plot of diversity index against time using a regression
model (Fig. 1) demonstrates that there is a significant increase in
the rate of accumulation of diversity after the rise in absolute CD8
cell count (ACD8) and absolute lymphocyte count (ALC) (refer-
ence 19 and Fig. 1B therein). Variant sites in which the majority
population is less than or equal to 95% of the overall population
are shown in Fig. 2. Analysis for insertions and deletions identifies
only a single insertion with a population prevalence of5%; this
insertion, at nucleotide position 232 in the G protein, leads to a
frame-shifted protein with a premature stop codon 24 amino ac-
ids downstream.
Haplotype analysis focused on regions with variants clustered
by proximity along the genome; the length of the sequencing reads
limited the distance over which haplotypes could be inferred.
Based on this analysis, cooccurring mutations that exceed 5% of
the overall number of reads covering the region include (i) the G
protein transmembrane domain (L54P and I60T), (ii) the G pro-
tein proximal ectodomain (L71P and L97P), and (iii) the N-ter-
minal region of the M2 protein, in which proline at amino acid
(aa) residue 31 was associated with several variants, including
P32L, P32H, A34V, and A34T, whereas serine and glutamine at aa
31were not associatedwith these variants (see Table S3 to S5 in the
supplemental material).
Patterns of diversity prior to and in the presence of trans-
plant-related immune response. The observation of diversity in
the RSV population from day 35 before transplant (D 35) to
D8 (Fig. 1), prior to the rise in ALC/ACD8 and cellular immu-
nity, could be due to neutral drift and/or to selection within the
host under innate immune or other immune pressures. In addi-
tion, some or all of the diversity seen at these time pointsmay have
been present in the inoculum infecting the patient, as can be seen
with other RNA viruses, such asHIV (25). Notably,most sites that
appear heterogeneous prior to day12 show no diversity subse-
quently (Fig. 2, G protein aa 140, 142, 150, 152, and 158). This
likely reflects the impact of the RSV population bottleneck and,
thereby, a reduction in genetic variation at the time of posttrans-
plant proliferation of lymphocytes.
The increase in diversity after day 12 is attributable to an
increase in the number of variant sites rather than an increase in
the amount of diversity at sites that previously had small amounts
of diversity (Fig. 2). Sites with markedly increased diversity after
day 12 include aa 78 and 102 in NS2, P-207, M-50, M-53, and
M-54; numerous sites in the transmembrane and proximal ect-














D35 KF973319 3.16E 06 14,967,434 0.74 100 964.415
D34 KF973320 2.14E 07 11,047,458 3.75 100 3,392.926
D33 KF973321 9.55E 06 9,462,236 1.74 100 1,369.774
D32 KF973322 6.03E 06 11,177,160 3.97 100 3,707.927
D31 KF973323 6.46E 06 6,976,464 6.13 100 3,606.695
D30 KF973324 1.20E 07 8,314,566 3.53 100 2,500.276
D29 NAd 3.80E 06 10,737,830 0.05 61.5c 93.47
D27 KF973325 3.24E 06 10,014,508 8.33 100 7,070.445
D22 KF973326 5.89E 06 10,845,850 1.18 100 1,097.51
D17 KF973327 8.91E 06 10,660,424 3.72 100 3,246.077
D14 KF973328 6.76E 06 11,967,902 9.97 100 9,862.39
D10 KF973329 1.23E 07 8,288,046 3.1 100 2,159.024
D8 KF973330 3.16E 06 10,717,942 0.65 100 620.338
D2 KF973331 6.46E 06 8,788,086 6.57 100 4,823.746
D1 KF973332 7.41E 06 10,493,098 0.68 100 631.46
D4 KF973333 1.29E 07 12,311,326 2.25 100 2,303.863
D8 KF973334 1.62E 07 8,718,476 20.2 100 14,563.966
D14 NA 4.07E 05 7,932,722 0.06 67.2c 71.7
D18 NA 7.24E 04 27,690,936 0.01 0 NA
D22 KF973335 1.10E 07 9,231,440 10.64 100 8,152.972
D26 KF973336 1.70E 06 6,596,080 1.43 100 811.788
D28 KF973337 6.61E 05 8,629,562 0.18 92.6 163.338
D32 KF973338 2.24E 07 10,535,286 10.04 100 8,539.512
D35 KF973339 1.02E 07 10,179,632 0.67 100 609.665
D39 KF973340 4.57E 06 15,089,126 1.54 100 1,912.278
D42 NA 1.70E 06 9,281,832 0.03 40.56c 58.01
a Patient samples were taken at various days pre- and post-bone marrow transplantation, with the day of transplant indexed by convention as day 0.
b RNA copies determined by RSV-A-specific quantitative reverse transcription-PCR.
c Assemblies are fragmented with many gaps between sequence contigs.
d NA, not applicable.
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odomain of the G protein, as well as G-192 and F-268; and aa 184
and 1280 in the L protein. Despite diversity demonstratingminor-
ity variants prior to the rise of lymphocyte count, no switch in
amino acid majority predominance occurs. After day 12, the
predominant amino acids switch at multiple sites (e.g., NS2-102,
P-207, G-56, G-60, G-292, F-268, and L-1280) (Fig. 2).
Several amino acid sites, including M2-31, G-229, and G-292,
show diversity that persists across all time points. In the case of
G-229, one subpopulation contains a premature stop codon,
truncating a large segment of the carboxy (C) terminus. The func-
tional implications of the other variants are unclear, but the per-
sistent polymorphisms at all three sites have at least two possible
causes: balancing selection driven by a pressure other than adap-
tive immunity, or sampling of populations from more than one
distinct subpopulation that do not directly compete with one an-
other, thereby maintaining polymorphisms.
Diversity in the G protein. The greatest diversity observed in
the samples appears in the G protein, which contains 45% of the
variant amino acid sites across all samples. The diversity in the G
protein is consistent with its role as amajor surface antigen of RSV
and relaxed selective constraints. The G protein product has two
forms: a transmembrane form (Gm), which functions as the at-
tachment glycoprotein for RSV, and a secreted form (Gs), which is
cleaved just downstream from the transmembrane domain and is
believed to function as an antigen decoy to allow evasion of anti-
body targeting (26, 27) and as a modulator of dendritic cell func-
tion (28).
The diversity within the G protein is notable for several fea-
tures. First, variants in G protein appear concentrated in three
regions (Fig. 3). These are (i) aa 33 to 97, extending across the
transmembrane domain and into the subsequent proximal ect-
odomain; (ii) aa 135 to 166, which includes the mucin-like do-
main and extends slightly into the central conserved domain; and
(iii) aa 204 to 292, which includes the mucin-like domain down-
stream from the central conserved domain. Second, the diversity
in these regions shows patterns that appear to change based on the
presence or absence of host functional lymphocytes. Diversity in
variable region ii is seen predominantly before the rise in ACD8/
ALC (Fig. 2). Diversity in variable region iii appears across all time
points, and diversity in variable region i is seen predominantly
after the rise in ACD8/ALC. Third, the within-host diversity seen
in the G protein contains features that have not been reported in
epidemiological studies of RSV-A (discussed below), raising ques-
tions about the extent to which consensus sequences mask true
viral population diversity and the role ofGprotein variants inRSV
quasi-species fitness in transmission and infection.
Thewithin-host diversity of the transmembrane domain is un-
expected, as the transmembrane domain is frequently highly con-
served in molecular epidemiology studies of the RSV-A G protein
(Fig. 3) (13). However, escape mutations in the transmembrane
domain have been demonstrated to emerge under selection by a
neutralizing antibody targeting the G protein (10). In that exam-
ple, reduced amounts of full-length G protein were detected on
the cell surface and incorporated into the virion, and increased
FIG 1 Plot of average diversity across the genome and lines reflecting the linear regression model coefficients; the R2 value refers to the overall fit of the model.
Note that day12 is the transition point, as it is the date of rise in absolute lymphocyte count (ALC) and absolute CD8 cell count (ACD8) after stem cell infusion
(see reference 19 and Fig. 1B therein). Open and closed circles represent diversity of samples prior to and after this point, respectively. The narrow arrowheads
indicate dates of palivizumab administration, and the wide arrowhead indicates the date of administration of polyclonal RSV-Ig.
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amounts of the secreted form were seen in the cell supernatant.
These results could reflect that mutations in the transmembrane
domain lead to diminished incorporation of theGprotein into the
virion, or that themutations lead to greater susceptibility to cleav-
age resulting in Gs. The observation, then, of transmembrane do-
main variants indicates an adaptive response to the pressure of
posttransplant immunity, either through diminished levels of Gm
leading to decreased antibody binding or elevated levels of Gs
functioning as decoys and decreasing the amount of available sol-
uble antibody.
Similarly, while a number of truncated G proteins have been
observed in RSV-B in vivo (29), we are unaware of reports of
truncatedGproteins in RSV-A in vivo. Studies of RSV escape from
antibody-mediated selection have shown that premature stop
codons in theC-terminal region can lead to antibody escape in cell
culture (11). The presence of premature stop codons at every time
point, however, suggests that the emergence of C-terminally trun-
cated G protein is not due solely to immune pressure. In addition,
the presence ofminority populations with premature stop codons
in the first mucin-like domain, prior to the heparin binding do-
main, during the pretransplant time points raises questions about
whether the variant-containing viruses are viable or fit. While in
vitro and mouse in vivo experiments have demonstrated that RSV
lacking the G protein can still infect cells, on the whole such virus
appears to infect less efficiently and replicatemore slowly (30, 31).
Diversity in the F protein. In the initial study of these samples,
consensus sequencing of the palivizumab binding domain of the
fusion (F) protein (aa 186 to 315) revealed no changes across the
sample set despite multiple administrations of palivizumab (19).
In contrast, deep sequencing of the viral populations (Fig. 2)
shows that minority populations contain known palivizumab es-
cape mutations at aa 268 (N268I [32]), 272 (both K272E and
K272N [33, 34]), and 275 (S275F [33, 34]); haplotype analysis
demonstrates that the variant alleles at positions 268, 272, and 275
occurred in separate populations. The presence of these minority
populations only after day 22 (13 days after the start of palivi-
zumab infusions) suggests that palivizumab exerted a selective
pressure in this population, consistent with what has been ob-
served rarely in palivizumab-treated populations (35).
The N268I variant at day39 is the only F protein variant that
becomes dominant. It is notable that the N268I variant does not
appear until day 28, after multiple administrations of palivi-
zumab, single-dose polyclonal RSV-Ig, and lymphocyte infusion
at the time of transplant. The more commonly epidemiologically
observed palivizumab escape variants at aa 272 and 275 appear
during the pre-engraftment period but remain minority alleles
despite multiple rounds of palivizumab administration, likely re-
flecting levels of palivizumab insufficient to generate enough se-
lective pressure on the viral population to overcome the presumed
fitness cost of the variants. It is also notable that the clinical sam-
ples evaluated all were obtained from the upper respiratory tract
(nasal aspirates), and the concentrations of functional RSV-neu-
FIG 2 Variable amino acids in the RSV samples. Each sample date is represented by one row. Genes are indicated in the top row, and amino acid sites (indexed
to the consensus sequence determined for the genome from the sample on day35 [D35]) below. Amino acids are considered variable if the dominant amino
acid call is at most 95% of the overall population for at least one of the time points. The height of the amino acid’s designated letter reflects its proportion in the
overall population. Asterisks represent stop codons. The horizontal line between days8 and22 represents the time after which lymphocytes and CD8 cells
became present (day12).
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tralizing palivizumab achievable in this anatomic site are approx-
imately 10-fold lower than those in the deeper lower respiratory
tract (36). Thus, palivizumab immune pressure measured in the
upper tract may not have been great enough to create and sustain
a consensus amino acid mutation within this anatomic site. The
additional mutations observed at aa 97, 176, 269, 446, and 526
predominantly appear after the rise in ACD8 and may reflect the
influence of specific or nonspecific immune responses. The im-
pact of these additional mutations on F protein function and viral
fitness are uncertain but bear further investigation as functional
immune epitopes.
Diversity in other regions of the genome. Variant sites ob-
served in the other 9 genes in the genome that arise after bone
marrow transplant and subsequent increase in ACD8/ALC may
reflect sites undergoing immune selection. Notable sites include
aa 78 and 102 in the nonstructural protein 2 (NS2; thought to
modulate the immune response through interaction with RIG-I
and decreased TRAF3 and STAT2); aa 53 and 207 in the phospho-
protein (P protein), thought to be a key component of the viral
RNA-dependent RNA polymerase complex); aa 50, 53, and 54 of
the matrix (M) protein; and aa 184 and 1280 in the polymerase (L
protein). Whether these variants emerged due to selection from
specific or nonspecific immunity, genetic hitchhiking (when the
frequency of a variant changes due to linkage with a positively
associated variant elsewhere in the genome), or neutral drift is
unclear. Comparison of the patterns of diversity in these genes in
the within-host sample and the samples frommolecular epidemi-
ological studies shows no clear overlap (see Fig. S2A to I in the
supplemental material).
While the rate of nonsynonymous versus synonymous substi-
tutions (dN/dS) can be helpful in specific situations in determin-
ing evidence of positive selection, dN/dS is difficult to interpret for
deep sequencing data of a population in which variants have not
yet fixed (37). Interpretability is further undermined by not being
able to ascribe linkage across full gene sequences: synonymous
sites might be polymorphic due to hitchhiking with nonsynony-
mous sites in a way that cannot be ascertained due to the short
sequence read lengths. Moreover, even without this problem, in
general, positive selection need not lead to elevated values of
dN/dS for within-population polymorphisms (37). Thus, in the
absence of a clear theoretical basis for interpreting the value of the
dN/dS statistic in the context of these deep sequencing data, we do
not present it and agree with the need for further study and devel-
opment of methods that permit interpretation of evidence of evo-
lutionary pressure in similar deep sequencing data sets.
Conclusions. This study presents the first whole-genome deep
sequencing analysis of clinical RSV samples, and the specific as-
pects of this chosen clinical case offer a unique opportunity to
evaluate the impact of differing levels of immune function on the
nature and extent of within-host viral population diversity. We
observe baseline diversity in the initial set of samples prior to bone
marrow transplant and increasing diversity correlating with the
presence of donor lymphocytes. The initial diversity may reflect a
mixed inoculum, drift, or anatomically distinct populations that
are captured in the upper respiratory clinical sampling procedure.
The data demonstrate increasing diversity in the presence of adap-
tive immunity, though it is unclear to what degree the diversity is
due to specific versus nonspecific inflammatory processes.
Through the detailed description of pathogen variation over
the course of an individual infection, this study raises a number of
questions regarding RSV pathogenesis and evolution. Do the pat-
terns of variation observed in this example represent the unique
circumstance of longstanding RSV infection and the combination
of bone marrow transplant and immunosuppression, or are they
representative of general RSV dynamics during individual infec-
tions? Do the variable sites which emerge after the rise in lympho-
FIG 3 Comparison of within-host and population-level G protein diversity. Black lines indicate the Shannon diversity index at each residue in the population-
wide analysis, and dashed red lines indicate the maximum Shannon diversity index across all time points in the within-host samples. See “Comparison of
within-host and population-wide diversity” inMaterials andMethods for a description of the analytical approach using the sequences reported in Table S1 in the
supplemental material.
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cyte count reflect specific or nonspecific immune pressure, other
selective pressures, or neutral drift? Does the abundance of vari-
ants in the G protein transmembrane domain indicate greater
production of Gs as an antibody decoy or another process, and
does the rare appearance of transmembrane domain variants in
population-wide surveys of G protein reflect the limited ability of
these variants to transmit and cause new infections? Are the vari-
able sites seen in genes coding for nonsurface antigens evidence of
selection in these genes, and if so, through what mechanism? Ad-
ditional deep sequencingwhole-genome studies over the course of
individual infections in immune-naive and immune-experienced
immunocompetent hosts will help address many of these ques-
tions.
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